Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the?CDMO continues to bulk up in a market that favors companies that can do it all.
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma") provided an update on several of its capital projects currently underway in both the United States and Belgium.
The bio-pharma display platform with 7 years of?experience?in?China,?BioPh China,?will be newly upgraded?to?bioLIVE?China?from?June 18-20, 2019. bioLIVE?China?2019 will focus on?life science, biotechnology, and innovative drugs;?lead bio-medicine technolo